SCHEMBL3261000

SCHEMBL3261000

CCc1ccc2cc(-c3cc(F)c(-c4cccc(F)c4)c(F)c3)ccc2c1

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.47
CYP1A2 P05177 1/20 0.44
CYP2A6 P11509 1/20 0.44
DHODH Q02127 1/20 0.43
CYP11B2 P19099 2/20 0.41
CYP17A1 P05093 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP11B1 P15538 1/20 0.41
ESR2 Q92731 4/20 0.39
ESR1 P03372 3/20 0.39
TNKS2 Q9H2K2 1/20 0.38
BCL2 P10415 1/20 0.35
GRM2 Q14416 1/20 0.35
ABL1 P00519 1/20 0.35
AKR1C3 P42330 1/20 0.35
AKR1C2 P52895 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3163338 0.90 TAAR1 (0.56) TAAR1CYP1A2CYP2A6DHODHCYP11B2
SCHEMBL3163249 0.89 TAAR1 (0.48) TAAR1DHODHCYP11B2CYP17A1CYP3A4
SCHEMBL3158271 0.88 TAAR1 (0.59) TAAR1CYP1A2CYP2A6CYP11B2CYP17A1
SCHEMBL3257252 0.87 CYP1A2 (0.43) TAAR1CYP1A2CYP2A6DHODHCYP17A1
SCHEMBL6059457 0.87 TAAR1 (0.46) TAAR1CYP11B2CYP17A1CYP3A4CYP11B1
SCHEMBL3153274 0.86 TAAR1 (0.47) TAAR1CYP1A2CYP2A6DHODHCYP11B2
SCHEMBL3153595 0.86 GCGR (0.45) TAAR1CYP11B2CYP17A1CYP3A4CYP11B1
SCHEMBL3255025 0.85 CYP1A2 (0.44) CYP1A2CYP2A6ESR2ESR1AKR1C3
SCHEMBL3259283 0.85 CYP1A2 (0.44) CYP1A2CYP2A6DHODHCYP11B2CYP17A1
SCHEMBL6059921 0.85 RARB (0.45) TAAR1DHODH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1452514-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2004-09-01 EP claimed
EP-1452514-B1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK & CHEMICALS (JP) 2010-03-31 EP disclosed
EP-1273562-B1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK & CHEMICALS (JP) 2009-07-22 EP disclosed
US-7145047-B2 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2006-12-05 US disclosed
EP-1452514-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2004-09-01 EP disclosed
US-20030136944-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-07-24 US disclosed
EP-1273562-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 2003-01-08 EP disclosed
US-6468607-B1 MISCIBILITY, LARGE BIREFRINGENCE INDEX, NO STRONGLY POLAR GROUP IN ITS MOLECULE AND THUS CAN ALSO BE USED FOR ACTIVE MATRIX DRIVING, WIDE TEMPERATURE RANGE AND REQUIRES A HIGH SPEED RESPONSE AND A LOW VOLTAGE DRIVING DAINIPPON INK AND CHEMICALS, INC. (JP) 2002-10-22 US disclosed
EP-0952135-A1 Naphthalene derivative and liquid crystal composition comprising the same DAINIPPON INK AND CHEMICALS, INC. (JP) 1999-10-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030136944-A1 Naphthalene derivative and liquid crystal composition comprising the same NLK, NOTCH1, NOTCH4 TAAR1 4184/4885CYP1A2 959/4885CYP2A6 3496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.